Continued access to inclisiran (Leqvio)

NHS England and Novartis negotiated access to inclisiran, an injectable cholesterol-lowering treatment for patients at risk of cardiovascular disease from April 2025. This agreement ensures comprehensive lipid management pathway coverage, providing an option for patients whose cholesterol has not been effectively reduced by statins alone or combined with ezetimibe. From 1 April 2025 GPs will be reimbursed at the rate of £60 which is a £10 increase on the previous rate of reimbursement. For general practice, inclisiran will continue to be available from the wholesaler (AAH). The deal maintains pricing for current and new NHS patients in England until December 2027, with arrangements ensuring that any revisions from January 2028 will not affect patients already receiving treatment.